| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elisa Mannini, Francesco Misirocchi, Stefania Lazzari, Giulia Balella, Dario Bottignole, Maddalena Frapporti, Lucia Zinno, Irene Florindo, Liborio Parrino, Carlotta Mutt. Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report. Epilepsy & behavior reports. vol 27. 2024-07-23. PMID:39040437. |
however, based on the available phase iii studies, the indications for this treatment have so far been restricted to lennox-gastaut syndrome (lgs), dravet syndrome (ds) and tuberous sclerosis complex (tsc) by regulatory authorities. |
2024-07-23 |
2024-07-25 |
Not clear |
| Robert T Wechsler, David E Burdette, Barry E Gidal, Ann Hyslop, Patricia E McGoldrick, Elizabeth A Thiele, James Valerian. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Epilepsia open. 2024-07-15. PMID:39007525. |
following the approval of epidiolex® (cannabidiol; cbd) for the treatment of seizures associated with lennox-gastaut syndrome (lgs), dravet syndrome (ds), and tuberous sclerosis complex (tsc), healthcare professionals (hcps) have had substantial experience in treating patients with epidiolex. |
2024-07-15 |
2024-07-18 |
Not clear |
| Giovanni Di Mauro, Giovanni Vietri, Loreta Quaranta, Fabio Placidi, Francesca Izzi, Alessandro Castelli, Andrea Pagano, Francesca Leonardis, Viviana De Angelis, Ciro Bianco, Maria Grazia Celeste, Nicola Biagio Mercuri, Claudio Liguor. Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series. CNS & neurological disorders drug targets. 2024-06-24. PMID:38910424. |
among novel antiseizure medications (asms), highly purified cannabidiol (hpcbd) has shown noteworthy efficacy in reducing seizures in lennox-gastaut syndrome (lgs), dravet syndrome (ds), and tuberous sclerosis complex (tsc). |
2024-06-24 |
2024-06-26 |
Not clear |
| Kinga Borowicz-Reutt, Julia Czernia, Marlena Krawczy. CBD in the Treatment of Epilepsy. Molecules (Basel, Switzerland). vol 29. issue 9. 2024-05-11. PMID:38731471. |
it has been several years since highly purified cannabidiol (cbd) was registered as a medication that can be used in children of at least 2 years of age to treat different types of seizures related to lennox-gastaut syndrome (lgs), dravet syndrome (ds), and more recently tuberous sclerosis complex (tsc). |
2024-05-11 |
2024-05-27 |
Not clear |
| Michael LoPresti, Ataru Igarashi, Yaoki Sonohara, Sally Bowditc. A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan. Epilepsy & behavior : E&B. vol 154. 2024-03-31. PMID:38555725. |
lennox-gastaut syndrome (lgs), dravet syndrome (ds), and tuberous sclerosis complex (tsc)-associated epilepsy are rare conditions associated with severe childhood-onset epilepsy. |
2024-03-31 |
2024-04-03 |
Not clear |
| Jingyi Tong, Tingting Ji, Ting Liu, Jiaqi Liu, Yibin Chen, Zongjun Li, Na Lu, Qifu L. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis. Epilepsy & behavior : E&B. vol 152. 2024-01-26. PMID:38277848. |
this study aimed to evaluate the efficacy and safety of six new antiseizure medications (asms) for adjunctive treatment in adult patients with focal epilepsy and adolescents with dravet syndrome (ds), lennox-gastaut syndrome (lgs), or tuberous sclerosis complex (tsc). |
2024-01-26 |
2024-01-29 |
Not clear |
| M Perriguey, M El Succar, A Clément, S Lagarde, O Ribes, X Dode, S Rheims, F Bartolome. High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies. Revue neurologique. 2023-10-08. PMID:37806886. |
lennox-gastaut syndrome (lgs), dravet syndrome (ds) and tuberous sclerosis complex (tsc) are diseases for which high-purified-cannabidiol (cbd) known as epidiolex® (gw pharma) can be prescribed in add-on of other medications in case of drug-resistance. |
2023-10-08 |
2023-10-15 |
Not clear |
| Darina Georgieva, James Langley, Katherine Hartkopf, Lisa Hawk, Amanda Margolis, Aaron Struck, Elizabeth Felton, David Hsu, Barry E Gida. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy & behavior : E&B. vol 141. 2023-03-09. PMID:36893722. |
epidiolex® (cbd) is fda-approved for seizures associated with lennox-gastaut syndrome (lgs), dravet syndrome (ds), and tuberous sclerosis complex (tsc). |
2023-03-09 |
2023-08-14 |
Not clear |
| Fabienne Kühne, Lena-Luise Becker, Thomas Bast, Astrid Bertsche, Ingo Borggraefe, Christian Malte Boßelmann, Jörg Fahrbach, Christoph Hertzberg, Nina A Herz, Martin Hirsch, Martin Holtkamp, Christine Janello, Gerhard Josef Kluger, Gerhard Kurlemann, Holger Lerche, Konstantin L Makridis, Felix von Podewils, Milka Pringsheim, Susanne Schubert-Bast, Juliane Schulz, Andreas Schulze-Bonhage, David Steinbart, Bernhard J Steinhoff, Adam Strzelczyk, Steffen Syrbe, Heike De Vries, Christiane Wagner, Johanna Wagner, Bernd Wilken, Christine Prager, Kerstin A Klotz, Angela M Kaind. Real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. Epilepsia open. 2023-01-24. PMID:36693811. |
cannabidiol (cbd) is approved for treatment of dravet syndrome (ds), lennox-gastaut syndrome (lgs), and tuberous sclerosis complex (tsc). |
2023-01-24 |
2023-08-14 |
Not clear |
| Gabriele Ruffolo, Alessandro Gaeta, Beatrice Cannata, Camilla Pinzaglia, Eleonora Aronica, Alessandra Morano, Pierangelo Cifelli, Eleonora Palm. GABAergic Neurotransmission in Human Tissues Is Modulated by Cannabidiol. Life (Basel, Switzerland). vol 12. issue 12. 2022-12-23. PMID:36556407. |
among the different pcbs, cannabidiol (cbd) has showed interesting biological properties, making it a promising molecule with a high security profile that has been approved for treatment as an add-on therapy in patients afflicted by severe pharmaco-resistant epilepsy, including dravet syndrome (ds), lennox-gastaut syndrome (lgs) and tuberous sclerosis complex (tsc). |
2022-12-23 |
2023-08-14 |
human |
| Ashna Talwar, Emily Estes, Rajender Aparasu, Doodipala Samba Redd. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Experimental neurology. 2022-10-07. PMID:36206805. |
in this study, we evaluated the overall clinical potential of oral cbd to treat refractory epilepsy in patients with dravet syndrome (ds), lennox-gastaut syndrome (lgs), and tuberous sclerosis complex (tsc) through a systematic review and meta-analysis. |
2022-10-07 |
2023-08-14 |
Not clear |
| Kishan Vyas, Hannah Luedke, Benjamin Ruban-Fel. Nordic treatment guidelines for rare epileptic conditions: A literature review. Brain and behavior. 2022-06-29. PMID:35765698. |
the onset of severe, drug-resistant seizures in early childhood is characteristic of the rare epileptic disorders lennox-gastaut syndrome (lgs), dravet syndrome (ds), and cdkl5 deficiency disorder (cdd) and is frequently observed in the rare genetic conditions tuberous sclerosis complex (tsc) and rett syndrome (rtt). |
2022-06-29 |
2023-08-14 |
Not clear |
| b' Val\\xc3\\xa9rie C\\xc3\\xb4t\\xc3\\xa9, \\xc3\\x88ve Lalancette, Inga S Knoth, Lucie C\\xc3\\xb4t\\xc3\\xa9, Kristian Agbogba, Phetsamone Vannasing, Philippe Major, Fanny Barlaam, Jacques Michaud, Sarah Lipp\\xc3\\xa. Distinct patterns of repetition suppression in Fragile\\xc2\\xa0X\\xc2\\xa0syndrome, down syndrome, tuberous sclerosis complex and mutations in SYNGAP1. Brain research. vol 1751. 2021-11-30. PMID:33189692.' |
one hundred and five participants, aged between 3 and 30 years old, composing four clinical id groups and one control group, were recruited: fragile x syndrome (fxs; n = 14), tuberous sclerosis complex (tsc; n = 9), down syndrome (ds; n = 19), syngap1 mutations (n = 8) and neurotypical controls (nt; n = 55)). |
2021-11-30 |
2023-08-13 |
human |
| Nancy L Reaven, Susan E Funk, Paul D Lyons, Tyler J Stor. The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis. Epilepsy & behavior : E&B. vol 93. 2020-06-23. PMID:30831405. |
lennox-gastaut syndrome (lgs), dravet syndrome (ds), and tuberous sclerosis complex (tsc) are representative conditions associated with frequent intractable seizures. |
2020-06-23 |
2023-08-13 |
Not clear |